地西他滨联合CAG方案治疗难治复发急性髓系白血病的疗效观察

Observation Decitabion Combine CAG Chemotherapy Regimen in Treating Relapsed and Refractory Acute Myeloid Leukemia Efficacy

目的 观察低剂量地西他滨联合CAG方案治疗难治复发急性髓系白血病的效果。方法 选择2013年12月1日至2016年3月1日在我院收治的复发难治性急性髓系白血病患者20例为研究对象,给予地西他滨（25 mg/d×3 d）联合CAG方案治疗,观察20例患者的临床疗效及不良反应。结果 20例患者中CR 10例,PR 5例,总有效率75%。1例患者出现Ⅰ度骨髓抑制,余患者出现Ⅱ~Ⅲ度骨髓抑制;5例出现肺部感染,其中1例因重症感染死亡。结论 地西他滨联合CAG方案治疗难治复发急性髓系白血病疗效显著,不良反应可耐受,推荐为难治复发急性髓系白血病患者化疗选择方案之一。

Objective Investigating the efficacy and safety of treating relapsed and refractory acute myeloid leukemia with decitabion combined with CAG chemotherapy regimen. Methods 20 cases of relapsed and refractory acute myeloid leukemia were treated with decitabine combined with CAG chemotherapy regimen, observe the efficacy and safety. Results 10 case was CR, 5 case PR, total effective rate 75%. 1 cases appeared Ⅰ degree of bone marrow suppression, other patients with Ⅱ-Ⅲ degree of bone marrow suppression; pulmonary infection occurred in 5 cases, of which 1 case died due to severe infection. Conclusion Decitabion combined with CAG chemotherapy regimen in treating relapsed and refractory acute myeloid leukemia is effective and safe.